Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01263028 · ClinicalTrials.gov registry record · NA
Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose
A NA study, sponsored by Kaiser Permanente.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT01263028: Clinical Trial NA study, sponsored by Kaiser Permanente.
NCT01263028 is a NA study that was terminated before completion, run by Kaiser Permanente. The registered enrollment target is 6 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01263028, a NA study, was terminated before completion, sponsored by Kaiser Permanente.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
Hypothesis: The supplementation of Ergocalciferol (Vitamin D2) to those with Vitamin D deficiency in the Chronic Kidney Disease population requiring recombinant human erythropoietin for the treatment of anemia related to kidney disease will reduce the dose of erythropoietin required to maintain a nonanemic state.
Interventions
- DRUG Ergocalciferol supplementation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2010-08 |
| Est. Completion | 2011-09 |
| Phase | NA |
Why NCT01263028 stopped before completion
NCT01263028 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Ergocalciferol supplementation is the first listed.
NCT01263028 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01263028 about?
NCT01263028 is a clinical study titled "Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose". Hypothesis: The supplementation of Ergocalciferol (Vitamin D2) to those with Vitamin D deficiency in the Chronic Kidney Disease population requiring recombinant human erythropoietin for the treatment of anemia related to kidney disease will reduce the dose of erythropoietin required to maintain a no...
What is the current status of trial NCT01263028?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2010-08. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01263028?
The interventions under investigation include: Ergocalciferol supplementation (DRUG).
Who is sponsoring clinical trial NCT01263028?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01263028's enrollment target sits among peer trials
6 1983rd of 2000 higher than 13 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia